fda warning letters compounded semaglutide telehealth 2024 2025 September 15, 2025: company must stop implying its GLP-1 is FDA-approved, warns – Partnership for Safe Medicines FDA issued 30 warning letters

Medical Review: A US-licensed physician reviews your profile and prescribes your starting dose

Here are some things to think about when buying one

Each time a multi-dose vial is accessed, there's a potential introduction of contaminants that can proliferate in the liquid medium

[1] [4] Wegovy, a higher-dose subcutaneous semaglutide formulation, received FDA approval for chronic weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia

Nutrition on GLP-1 therapy should emphasize omega-3 fatty acids, polyphenol-rich foods, and adequate protein to support immune function and tissue repair

Where one site might emphasize jackpots, another might spotlight live tables or themed events